Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding EBIT per Share

The EBIT per Share of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Oct 18, 2026 is 2.87 CNY. In the previous year, EBIT per Share was 3.58 CNY — a change of -19.84% (lower).

EBIT per Share

2.87CNY

YoY

-19.84%

Last updated:

EBIT per Share of Tibet Rhodiola Pharmaceutical Holding is 2025 2.87 CNY. EBIT per Share of Tibet Rhodiola Pharmaceutical Holding was 2024 3.58 CNY. It decreases by -19.84% lower compared to the previous year.

The Tibet Rhodiola Pharmaceutical Holding EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
1.07 CNY
Jan 1, 2021
0.78 CNY
Jan 1, 2022
1.43 CNY
Jan 1, 2023
2.78 CNY
Jan 1, 2024
3.58 CNY
Jan 1, 2025
2.87 CNY
Jan 1, 2026 (e)
8.99 CNY
Jan 1, 2027 (e)
0.00 CNY
The Tibet Rhodiola Pharmaceutical Holding EBIT per Share history
YEAREBIT per ShareYoY
est0.00CNY-100.00%
est8.99CNY+213.51%
2.87CNY-19.84%
3.58CNY+28.77%
2.78CNY+94.95%
1.43CNY+81.87%
0.78CNY-26.47%
1.07CNY+0.89%
1.06CNY+41.76%
0.75CNY+13.94%
0.65CNY-12.03%
0.74CNY+82.36%
0.41CNY+311.64%
0.10CNY+204.41%
0.03CNY-69.28%
0.11CNY+265.10%
0.03CNY-52.32%
0.06CNY+70.55%
0.04CNY-273.43%
-0.02CNY-97.07%
-0.70CNY+1,276.75%
-0.05CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co, listed on the Shanghai Stock Exchange under ticker 600211.SS, operates as a pharmaceutical company based in Lhasa, China. The company's ISIN is CNE000000ZW7. Founded through an IPO on July 21, 1999, it specializes in the manufacture and wholesale of pharmaceutical products. Its headquarters are located in Lhasa, Xizang, and it employs 615 full-time staff. The firm distributes proprietary drug products and processes pharmaceuticals, conducting business primarily across South China, North China, East China, Central China, and overseas markets. The company's website is http://www.xzyy.cn. It does not provide details on specific products, acquisitions, or financial figures beyond the IPO date and employee count. The company focuses on pharmaceutical manufacturing and distribution within its operational regions, with no additional information provided on its product lines or market share. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

EBIT per Share of Tibet Rhodiola Pharmaceutical Holding is 2.87 CNY in 2025.

EBIT per Share of Tibet Rhodiola Pharmaceutical Holding changed from 3.58 CNY to 2.87 CNY, representing a -19.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Tibet Rhodiola Pharmaceutical Holding

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding